SynthesisScientific reports2017
Decreased circulating Zinc levels in Parkinson's disease: a meta-analysis study.
Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Pooled it
- Actual Data on Essential Trace Elements in Parkinson's Disease.Nutrients · 2025Pooled it
- The Changes of Blood and CSF Ion Levels in Depressed Patients: a Systematic Review and Meta-analysis.Molecular neurobiology · 2024Pooled it
- The role of zinc homeostasis in major depressive disorder: heterogeneous pathological mechanisms and therapeutic implications.Annals of medicine · 2026Review
- Cadmium-Induced Toxicity as a Pathophysiological Mechanism for Parkinson's Disease Onset in Individuals with Iron and Zinc Deficiencies and Chronic Obstructive Pulmonary Disease.Neurology international · 2026Review
- Association of peripheral and CSF zinc levels with Parkinson's disease: A systematic review and meta-analysis.IBRO neuroscience reports · 2026Review
- Isotopically enrichedScientific reports · 2026Article
- Environmental toxins in neurodegeneration - a narrative review.Neurological research and practice · 2025Review
- ZnJournal of the American Chemical Society · 2025Article
- Tissue zinc restoration alleviates the levodopa-induced dyskinesia via impeding ERK phosphorylation.European journal of nutrition · 2025Article
- Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.Signal transduction and targeted therapy · 2025Review
- Proteomics analysis in rats reveals convergent mechanisms between major depressive disorder and dietary zinc deficiency.Pharmacological reports : PR · 2025Article
- Aspergillusidone G Potentiates the Anti-Inflammatory Effects of Polaprezinc in LPS-Induced BV2 Microglia: A Bioinformatics and Experimental Study.Marine drugs · 2024Article
- Bidirectional two-sample Mendelian randomization analysis identifies causal associations between oxidative stress and Parkinson's disease.Frontiers in aging neuroscience · 2024Article
- Review
- Zinc and Central Nervous System Disorders.Nutrients · 2023Review
- Serum zinc deficiency could be associated with dementia conversion in Parkinson's disease.Frontiers in aging neuroscience · 2023Article
- Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson's disease.Frontiers in aging neuroscience · 2023Article
- Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases.BioMed research international · 2023Review
- Neuronal signalling of zinc: from detection and modulation to function.Open biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no consensus on the involvement of zinc (Zn) dysfunctions in Parkinson's Disease (PD). We performed a meta-analysis to evaluate whether circulating Zn levels in the serum, plasma, and cerebrospinal fluid (CSF) are altered in PD. Twenty-three published studies were selected by searching the databases of PubMed and China National Knowledge Infrastructure (CNKI). A total of 803 PD patients and 796 controls, 342 PD patients and 392 controls, and 135 PD patients and 93 controls were included to study Zn levels in the serum, plasma, and CSF, respectively. Our meta-analysis showed that the serum Zn levels were significantly lower in PD patients compared with health controls (SMD = -0.59; 95% CI [-1.06, -0.12]; P = 0.014). A reduced Zn levels in PD patients were found when serum and plasma studies were analyzed together (SMD = -0.60, 95% CI [-0.98; -0.22]; p = 0.002). PD patients had a tendency toward reduced CSF Zn levels compared with health controls (SMD = -0.50; 95% CI [-1.76, 0.76]; P = 0.439), but no statistical significance was obtained and this data did not allow conclusions due to a small sample size of CSF studies. This study suggests that reduced Zn levels in the serum and plasma are associated with an increased risk for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.